Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

Subgroup analyses reveal GLP-1 RAs may reduce alcohol cravings and brain cue reactivity. Study: Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption ...

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. It has ...

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are tirzepatide (Zepbound) and semaglutide (Wegovy). Semaglutide was originally ...

ABSTRACT: The increasing use of glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide, for weight management has sparked interest in understanding their broader physiological ...

Diabetes Care. 2006;29(2):435-449.

pennmedicine.upenn.edu Background/aims Glucagon-like peptide-1 receptor (GLP-1R) agonists regulate blood glucose and are commonly used to treat type 2 diabetes mellitus. Recent work showed that ...

Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral ...

HANOI, VIETNAM / ACCESS Newswire / April 14, 2025 / Together with world-renowned scientists including Prof. Joel F. Habener, ...